IP Library Granted Patent US 12,723,233
Granted Patent B2
US 12,723,233 · App. 17/416,200 · Granted Sep 1, 2026

Media and methods for differentiating natural killer cells

Inventors: Nooshin Tabatabaei-Zavareh (Vancouver, CA); Albertus Wernerus Wognum (Vancouver, CA)
Assignee: Stemcell Technologies Canada Inc.
C12N5/0646A61K40/15A61K40/428A61K2239/48C12N2500/90C12N2501/125C12N2501/2302C12N2501/2307C12N2501/2312C12N2501/2315C12N2501/2321C12N2501/26C12N2501/38C12N2502/14C12N2506/11C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,723,233
App. No.
17/416,200
Granted
Sep 1, 2026
Kind
B2
Abstract

Media and methods for differentiating NK progenitor cells into NK cells are disclosed. The NK differentiation media comprises a pyrimidoindole compound such as UM171 or UM729.

Claims (24)

1 . A method for differentiating NK cells, comprising:

providing a population of NK cell progenitors, wherein the population of NK cell progenitors arise in contact with a NK cell progenitor differentiation medium and a stroma cell replacement comprising components selected from fibronectin, whether full-length or a fragment thereof, VCAM-1, and an immobilized Notch ligand; and

contacting the population of NK cell progenitors in culture with an NK cell differentiation medium comprising a basal medium, IL-15 and a pyrimidoindole compound at a concentration between 10 nM and 3 μM and for a time sufficient to yield NK cells,

wherein the NK cells co-express i) CD56, NKG2D and NKp44, or ii) CD56, NKG2D and NKp30,

wherein an increased frequency and/or yield of NK cells co-expressing i) CD56, NKG2D and NKp44, or ii) CD56, NKG2D and NKp30 is obtained when contacting the population of NK cell progenitors with the NK cell differentiation medium as compared to when the NK cells are differentiated from the population of NK cell progenitors in a NK cell differentiation medium devoid of an added pyrimidoindole compound, and

wherein the NK cells produce intracellular interferon γ upon stimulation.

2 . The method according to claim 1 , wherein the population of NK cell progenitors express CD7 or CD5, or both.

3 . The method according to claim 1 , wherein the NK cells increase in frequency during the contacting step or increase in number during the contacting step, or both.

4 . The method according to claim 1 , wherein the population of NK cell progenitors increase or decrease in frequency or number during the contacting step.

5 . The method according to claim 1 , wherein the providing and contacting steps are not in the presence of stromal cells or a stroma cell replacement.

6 . The method according to claim 1 , wherein the providing and contacting steps are not in the presence of an aryl hydrocarbon receptor antagonist.

7 . The method according to claim 1 , wherein the time is at least 1 week or about 2 weeks.

8 . The method according to claim 1 , wherein the NK cells are cytotoxic.

9 . The method according to claim 1 , wherein the population of NK cell progenitors is derived or isolated from a primary sample.

10 . The method according to claim 1 , wherein the population of NK cells is differentiated from a pluripotent stem cell.

11 . The method of claim 1 , wherein less than 5% of the NK cells express CD3.

12 . A method for differentiating NK cells, comprising:

providing a population of NK cell progenitors, wherein the population of NK cell progenitors arise in contact with a NK cell progenitor differentiation medium and a stroma cell replacement comprising components selected from fibronectin, whether full-length or a fragment thereof, VCAM-1, and an immobilized Notch ligand; and

contacting the population of NK cell progenitors in culture with an NK cell differentiation medium comprising a basal medium, IL-15 and a pyrimidoindole compound at a concentration between 10 nM and 3 μM and for a time sufficient to yield NK cells,

wherein the NK cells co-express i) CD56, NKG2D and NKp44, or ii) CD56, NKG2D and NKp30,

wherein an increased frequency and/or yield of NK cells co-expressing i) CD56, NKG2D and NKp44, or ii) CD56, NKG2D and NKp30 is obtained when contacting the population of NK cell progenitors with the NK cell differentiation medium as compared to when the NK cells are differentiated from the population of NK cell progenitors in an NK cell differentiation medium devoid of an added pyrimidoindole compound,

wherein less than 5% of the NK cells express CD3, and

wherein the NK cells produce intracellular interferon γ upon stimulation.

13 . The method of claim 12 , wherein the population of NK cell progenitors express CD7 or CD5, or both.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2022
From: STEMCELL TECHNOLOGIES CANADA INC.
To: HSBC BANK CANADA
Reel/Frame 060544/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2021
From: TABATABAEI-ZAVAREH, NOOSHIN; WOGNUM, ALBERTUS WERNERUS
To: STEMCELL TECHNOLOGIES CANADA INC.
Reel/Frame 056587/0283 →
Continuity (2)
Provisional Application 62783341 · Dec 21, 2018
Related Publication 20220056412A1 · Feb 24, 2022
References Cited (19)
US 9585914B2 · Dilber · 2017 [cited by examiner]
US 10828329B2 · Laganière · 2020 [cited by examiner]
US 11702635B2 · Hernandez · 2023 [cited by examiner]
US 20150374754A1 · Dilber et al. · 2015 [cited by applicant]
US 20190209618A1 · Hope · 2019 [cited by examiner]
CA 2972662A1 · 2016 [cited by applicant]
WO WO2016191879A1 · 2016 [cited by examiner]
WO 2017173551A1 · 2017 [cited by applicant]
Li et al, (Stem Cell Res. May 2017:21:32-39. doi: 10.1016/j.scr.2017.03.014. Epub Mar. 21, 2017 (Year: 2017). [cited by examiner]
Tabatabaei-Zavareh et al. (Differentiation of hematopoietic stem and progenitor cells to NK cells in a stroma free, serum-free culture system. Journal of Immunology, May 1, 2018, vol. 200, issue 1, Supplement, abstract … [cited by examiner]
Mesquitta et al. (Pyrimido-indole derivative, UM171 promotes differentiation and expansion of myeloid progenitors and NK cells from human pluripotent stem cells, Experimental Hematology, 64(22), Aug. 2018, (Year: 2018) … [cited by examiner]
Tabatabaei-Zavareh et al. (Differentiation of hematopoietic stem and progenitor cells to NK cells in a stroma free, serum-free culture system. Journal of Immunology, May 1, 2018, vol. 200, issue 1, Supplement, abstract … [cited by examiner]
Mesquitta et al. (Pyrimidoindole derivative, UM171 promotes differentiation and expansion of myeloid progenitors and NK cells from human pluripotent stem cells, Experimental Hematology, 64(22), Aug. 2018) (Year: 2018). [cited by examiner]
Mesquitta, WT. et al., Pyrimido-indole derivative, UM171 promotes differentiation and expansion of myeloid progenitors and NK cells from human pluripotent stem cells, Experimental Hematology, 64(22), Aug. 2018. [cited by applicant]
Mesquitta, W-T et al., Pyrimido-indole derivative, UM171 expands distinct types of myeloid and lymphoid progenitors from human pluripotent stem cells. Blood, Nov. 29, 2018, vol. 132, Supplement 1:3835 (abstract). [cited by applicant]
STEMCELL Technologies. Expansion and Differentiation of Hematopoietic Stem and Progenitor Cells into Natural Killer Cells Using StemSpan Medium and Supplements. Technical Bulletin, Document #DX22912, Version 1.0.01, Nov… [cited by applicant]
Tabatabaei-Zavareh, N. et al., Differentiation of hematopoietic stem and progenitor cells to NK cells in a stroma-free, serum-free culture system. Journal of Immunology, May 1, 2018, vol. 200, issue 1, Supplement, abstr… [cited by applicant]
Journal of Immunology, vol. 200, Issue Supplement 1, p. 103.4(May 1, 2018). [cited by applicant]
Science, vol. 345(6203), p. 1509-1512(Sep. 19, 2014.). [cited by applicant]